ARTICLE | Finance
2002 Financial Markets Preview: Repricing the venture space
January 14, 2002 8:00 AM UTC
Life science venture capital firms raised record money last year, but some later stage companies are having difficulty raising equity because the valuations from their last round - priced in the waning days of the genomics bubble - got way ahead of their fundamentals.
Valuations are coming down - in some cases, deals are getting shopped at less than 50% of their prior valuation. But investors continue to play a waiting game, as they - in Wall Street parlance - don't want to catch a falling knife. ...